Autres langues Mustang Bio, Inc.

Actions

MBIO

US62818Q2030

Temps Différé Nasdaq Autres places de cotation 18:16:01 06/05/2024			Varia. 5j.	Varia. 1 janv.
0,3025 ^USD	-4,81 %		+30,51 %	-77,09 %

30/04	Mustang Bio fixe le prix de l'offre publique de 16,9 millions d'actions et des bons de souscription qui l'accompagnent	MT
28/03	Mustang Bio, Inc. annonce sa vision de l'expansion de la plateforme de thérapie CAR T dans les maladies auto-immunes	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Mustang Bio Announces Closing of $4 Million Public Offering	02/05
Mustang Bio, Inc. announced that it has received $3.3 million in funding	02/05
Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants	30/04
Mustang Bio Announces Pricing of $4 Million Public Offering	30/04
Mustang Bio : Results of Operations and Financial Condition - Form 8-K	29/04
Mustang Bio, Inc. announced that it expects to receive $3.3 million in funding	29/04
North American Morning Briefing : Stock Futures Rise Despite Middle East Tensions	15/04
Mustang Bio : Costs Associated with Exit/Disposal - Form 8-K	12/04
Mustang Bio : Corporate Presentation	01/04
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	28/03
Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	28/03
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	11/03
Mustang Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11/03
City of Hope-developed chimeric antigen receptor T cell therapy shows clinical activity in patients with aggressive brain tumors in a Phase 1 trial	08/03
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma	07/03
Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma	07/03
Mustang Bio : Corporate Presentation	01/03
Mustang Bio, Inc Appoints James Murphy as Interim Chief Financial Officer	25/01
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference	11/01
Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer	12/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Mustang Bio, Inc.

Actions

MBIO

US62818Q2030

Autres langues

Filtres